Our experiences with 90Y-DOTATOC therapy for neuroendocrine tumors (NETS)

In the last 30 years the incidence of neuroendocrine tumors showed a five fold increase. This disease group includes tumors with heterogeneous behavior, and the treatment may differ significantly. The WHO's 2010 classification based on pathological characteristics provides the basis of treatment. Among the non-surgical therapeutical options, in addition to somatostatin analogues, interferons, endoradiotherapy and chemotherapeutic agents, targeted therapies including tyrosine kinase and m-TOR inhibitors have also appeared. Clinical studies proved that the long-acting somatostatin analogue Sandostatin LAR has anti…